Cost-minimization Analysis of Ranibizumab versus Aflibercept in the Treatment of Neovascular Age-related Macular Degeneration in Colombia

References

• Wong WL, Su X, Li X, et al. Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: a systematic review and meta-analysis. Lancet Glob Health. 2014;2:e106–16. doi:10.1016/S2214-109X(13)70145-1.
   PubMed Web of Science ®Google Scholar
• https://www.dane.gov.co/index.php/estadisticas-por-tema/demografia-y-poblacion/proyecciones-de-poblacion. Accessed February 7, 2020.
   Google Scholar
• Nguyen CL, Oh LJ, Wong E, Wei J, Chilov M. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials. BMC Ophthalmol. 2018;18(1):130. Published 2018 May 30. doi:10.1186/s12886-018-0785-3.
   PubMedGoogle Scholar
• Gillies MC, Hunyor AP, Arnold JJ, et al. Effect of ranibizumab and aflibercept on best-corrected visual acuity in treat-and-extend for neovascular age related macular degeneration. A randomized clinical trial. JAMA Ophthalmol. 2019. doi:10.1001/jamaophthalmol.2018.6776.
   Web of Science ®Google Scholar
• Gillies MC, Hunyor AP, Arnold JJ, et al. Macular atrophy in neovascular age-related macular degeneration a randomized clinical trial comparing ranibizumab and aflibercept (RIVAL study). Ophthalmology. 2020;127:198–210. doi:10.1016/j.ophtha.2019.08.023.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Chioreso C, Schweizer ML, Abramoff D. Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies. Invest Ophthalmol Vis Sci. 2017;58:5616–5627. doi:10.1167/iovs.17-22471.
   PubMed Web of Science ®Google Scholar
• Kim LN, Mehta H, Brthelemes D, et al. Meta-analysis of real-world outcomes of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration. Retina. 2016;36:141–143. Accessed 20 July 2019. doi:10.1097/IAE.0000000000001142.
   Web of Science ®Google Scholar
• www.invima.gov.co/consultas-registros-sanitarios.html. Accessed on 20 July 2019.
   Google Scholar
• https://www.asrs.org/content/documents/2015_global_trends_in_retina_survey_for_website.pdf. Accessed 20 July 2019.
   Google Scholar
• Elshout M, van der Reis MI, Webers CA, Schouten JS. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters. Graefes Arch Clin Exp Ophthalmol. 2014;252(12):1911–1920. doi:10.1007/s00417-014-2641-3.
   PubMed Web of Science ®Google Scholar
• Low A, Faridi A, Bhavsar KV, et al. Comparative effectiveness and harms of intravitreal antivascular endothelial growth factor agents for three retinal conditions: a systematic review and meta-analysis. Br J Ophthalmol. 2019;103:442–451. doi:10.1136/bjophthalmol-2018-312691.
   PubMed Web of Science ®Google Scholar
• Takura T. An evaluation of clinical economics and cases of cost-effectiveness. Intern Med. 2018;57(9):1191–1200. doi:10.2169/internalmedicine.9835-17.
   PubMed Web of Science ®Google Scholar
• Parikh RP, Avery RL, Saroj N, Thompson D, Freund B. Incidence of new choroidal neovascularizacion in fellow eyes of patients with age-related macular degeneration treated with intravitreal aflibercept of ranibizumab. JAMA Ophthalmol. 2019. doi:10.1001/jamaophthalmol.2019.1947.
   Google Scholar
• Rodríguez FJ, Posso H, Abdala C, Vergara O, Varón C. Prevalencia y factores de riesgo en degeneración macular relacionada con la edad en Colombia. Revista Sociedad Colombiana de Oftalmología. 2009;42:117–127.
   Google Scholar
• Hernandez L, Lanitis T, Cele C, Toro-Diaz H, Gibson A, Kuznik A. Intravitreal aflibercept versuis ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis. J Manag Care Spec Pharm. 2018 Jul;24(7):608–616. doi:10.18553/jmcp.2018.24.7.608.
   PubMed Web of Science ®Google Scholar
• Zheng DD, Christ SL, Lam BL, et al. Visual acuity and increased mortality: the role of allostatic load and functional status. Invest Ophthalmol Vis Sci. 2014; 55(8):5144–5150. Published 2014 July 24. doi:10.1167/iovs.14-14202.
   PubMed Web of Science ®Google Scholar
• Traine PG, Pfister IB, Zandio S, et al. Long-term outcome of intravitreal aflibercept treatment for neovascular age-related macular degeneration using a “treat-and-extend “regimen. Ophthalmol Retina;2019:1–7.
   PubMedGoogle Scholar
• https://www.minsalud.gov.co/salud/MT/Paginas/medicamentosregulacion-precios.aspx. Accessed on February 20, 2020
   Google Scholar
• http://www.banrep.gov.co/es/estadisticas/trm. Accessed on February 9, 2020
   Google Scholar
• Schmier JK, Hulme-Lowe CK. Cost-effectiveness models in age-related macular degeneration: issues and challenges. PharmocoEconomics. 2015. doi:10.1007/s40273-015-0347-y.
   Web of Science ®Google Scholar
• Husereau D, Drummond M, Petrou S, et al. Consolidated Health Economic Evaluation Reporting Standards (CHEERS) – explanation and Elaboration: A report of the ISPOR Health Economic Evaluation Publication Guidelines Good Reporting Practices Task Force. Value Health. 2013;16:231–250. doi:10.1016/j.jval.2013.02.002.
   PubMed Web of Science ®Google Scholar
• Mulligan K, Seabury SA, Dugel PU, Blim JF, Goldman DP, Humayun MS. Economic value of anti–vascular endothelial growth factor treatment for patients with wet age-related macular degeneration in the United States. JAMA Ophthalmol. 2020;138(1):40–47. doi:10.1001/jamaophthalmol.2019.4557.
   PubMed Web of Science ®Google Scholar
• Pongsachareonnont P, Mak MYK, Hurst CP, Lam WC. Neovascular age-related macular degeneration: intraocular inflammatory cytokines in the poor responder to ranibizumab treatment. Clin Ophthalmol. 2018;26:1877–1885. doi:10.2147/OPTH.S171636. PMID: 30310267; PMCID: PMC6165786.
   Google Scholar
• Mantel I, Gillies M, Souied EH.. Switching between ranibizumab and aflibercept for the treatment of age-related macular degeneration. Surv Ophthalmol 2018;63:638–345.
   Google Scholar